ANTX

SEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 3

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.(

Disclosed balance after: 2,169,680

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050853 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P

Disclosed balance after: 411,759

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050853 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,176,840

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 411,759

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-050851 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,176,840

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-048422 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.(

Disclosed balance after: 411,893

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-048422 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,177,547

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-048436 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P

Disclosed balance after: 411,893

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-048436 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,177,547

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · ownership.nature: . Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047312 · ownership.xml · nonDerivative · entry 4

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.(

Disclosed balance after: 411,957

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047312 · ownership.xml · nonDerivative · entry 3

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,177,883

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 4

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 411,957

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 3

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,177,883

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047312 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.(

Disclosed balance after: 412,494

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047312 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,180,724

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 412,494

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-047311 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,180,724

F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-044594 · ownership.xml · nonDerivative · entry 2

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 413,092

F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-044594 · ownership.xml · nonDerivative · entry 1

Adjuvant Global Health Technology Fund, L.P. · CIK 0001783165 · 10% owner

Adjuvant Global Health Technology Fund DE, L.P. · CIK 0001799812 · 10% owner

Adjuvant Capital GP, L.P. · CIK 0001935100 · 10% owner

Adjuvant Capital Management, LLC · CIK 0001935084 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,183,888

F1 · ownership.direct: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-044593 · ownership.xml · nonDerivative · entry 2

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund DE, L.P.

Disclosed balance after: 413,092

F2 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0000950170-23-044593 · ownership.xml · nonDerivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Adjuvant Global Health Technology Fund, L.P.

Disclosed balance after: 2,183,888

F1 · ownership.nature: Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.

SEC source: 0001104659-23-094274 · tm2324309-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 5,135,683

F1 · price: Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on August 16, 2023.

F1 · ownership.nature: Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on August 16, 2023.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0000899243-23-015326 · doc4.xml · derivative · entry 1

Aziz Kabeer · CIK 0001914847 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015321 · doc4.xml · derivative · entry 1

Zakrzewski Joseph S · CIK 0001331852 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015320 · doc4.xml · derivative · entry 1

FitzPatrick Margaret M · CIK 0001873879 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015317 · doc4.xml · derivative · entry 1

Wong Stephanie · CIK 0001555744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015314 · doc4.xml · derivative · entry 1

Marks Gilbert Lynn · CIK 0001916940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015313 · doc4.xml · derivative · entry 1

Martin Patricia A. · CIK 0001916764 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015310 · doc4.xml · derivative · entry 1

Spigelman Melvin K · CIK 0001339901 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-015307 · doc4.xml · derivative · entry 1

Readnour Robin Shane · CIK 0001914883 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,742

Underlying: Common Stock · 23,742 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date.

SEC source: 0000899243-23-013012 · doc4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,015,766

F1 · ownership.nature: Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.

SEC source: 0000899243-23-006150 · doc4.xml · derivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 267,650

Underlying: Common Stock · 267,650 shares

Expires 2033-02-22

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005554 · doc4.xml · derivative · entry 1

Eizen Joshua M · CIK 0001949621 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,150

Underlying: Common Stock · 50,150 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005558 · doc4.xml · derivative · entry 1

Day Lucy · CIK 0001914510 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,300

Underlying: Common Stock · 82,300 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005557 · doc4.xml · derivative · entry 1

Chanda Sanjay · CIK 0001571820 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,950

Underlying: Common Stock · 57,950 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005555 · doc4.xml · derivative · entry 1

Eckburg Paul · CIK 0001914512 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,950

Underlying: Common Stock · 70,950 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005550 · doc4.xml · derivative · entry 1

Nazak Michael Adrian · CIK 0001799731 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,600

Underlying: Common Stock · 16,600 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-23-005545 · doc4.xml · derivative · entry 1

Krause Kevin Michael · CIK 0001916925 · Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,200

Underlying: Common Stock · 62,200 shares

Expires 2033-02-14

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.

SEC source: 0000899243-22-035782 · doc4.xml · nonDerivative · entry 2

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,907

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035782 · doc4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,930

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.85. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 3

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,907

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 2

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,018

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035472 · doc4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,273

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 5

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,907

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 4

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,943

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 3

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,110

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 2

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,938

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-035311 · doc4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,021

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-034840 · doc4.xml · nonDerivative · entry 2

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,907

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-22-034840 · doc4.xml · nonDerivative · entry 1

Easom Eric · CIK 0001914503 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,451

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.